MRK ▲ +0.6% - Merck & Co., Inc.
$MRK - Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
13-NOV-2026 06:37 AM ET
Share this post
More filings for $MRK
MRK ▲ +0.6% - Merck & Co., Inc.Nov 13, 2026MRK ▲ +1.2% - Merck & Co., Inc.Nov 9, 2026MRK ▲ +0.9% - Merck & Co., Inc.Nov 9, 2026MRK ▼ -0.5% - Merck & Co., Inc.Nov 3, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 29, 2026MRK ▼ -2.4% - Merck & Co., Inc.Oct 26, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment